GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Adverum Biotechnologies
Adverum is a biotech company developing gene therapy for eye diseases. Its price chart is a dramatic story of the promise of its technology and the serious safety issues that led to a stock collapse and a shift in strategy.
Share prices of companies in the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapy for the treatment of severe eye diseases such as wet age-related macular degeneration. We've classified it in the "Pharma Eyes" segment. The chart below shows the overall dynamics in the ophthalmic gene therapy sector, which could change the standard of care.
Broad Market Index - GURU.Markets
Adverum Biotechnologies is a biopharmaceutical company developing gene therapy for the treatment of severe eye diseases. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Adverum compares to it.
Change in the price of a company, segment, and market as a whole per day
ADVM - Daily change in the company's share price Adverum Biotechnologies
Adverum Biotechnologies' daily share price fluctuations reflect the extreme volatility inherent in gene therapy companies. This metric is a measure of sensitivity to clinical trial data and drug safety issues.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Adverum Biotechnologies, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with ADVM, which focuses on ocular gene therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Adverum Biotechnologies is a biotech company specializing in gene therapy for eye diseases. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Adverum Biotechnologies
For Adverum Biotechnologies, the year-over-year trend is a story about developing gene therapy for eye diseases. Its 12-month market cap is entirely dependent on clinical trial data, particularly safety. Overcoming side effects is a fundamental step for the future of its promising drug.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Adverum Biotechnologies, Inc. is a clinical-stage biotech company developing gene therapy for eye diseases. Its stock performance is entirely dependent on the results of its clinical trials, which have been fraught with difficulties, reflecting the high risks of this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adverum is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Adverum Biotechnologies
Adverum Biotechnologies is a biotech company developing gene therapies for eye diseases. Its monthly performance is entirely dependent on the results of its clinical trials. News about the safety and efficacy of its drugs causes sharp fluctuations in its price.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Gene therapy in ophthalmology is an area of great promise and high risk. The dynamics of this biotech sector, shown in the chart, reflect its extreme volatility, where clinical news is everything. It's in this environment that companies like Adverum Biotechnologies are pursuing their developments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adverum Biotechnologies, a company developing gene therapy for the eye, is a high-risk biotech. Its shares can soar by thousands of percent or plummet to zero on news about the safety and efficacy of its drugs, completely ignoring the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Adverum Biotechnologies
The short-term price volatility of Adverum, a biotech company developing gene therapy for eye diseases, is extremely high. News about the safety and effectiveness of its therapy in clinical trials is a key factor driving explosive stock price movements.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Adverum Biotechnologies shares, like the entire gene therapy sector, are moving against a backdrop of scientific breakthroughs and safety news. These factors are creating extreme volatility for everyone. The chart below will show how the company fares in this innovative yet risky field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Adverum Biotechnologies shares, like the entire gene therapy sector, are moving against a backdrop of scientific breakthroughs and safety news. These factors are creating extreme volatility for everyone. The chart below will show how the company fares in this innovative yet risky field.
Market capitalization of the company, segment and market as a whole
ADVM - Market capitalization of the company Adverum Biotechnologies
Adverum's market capitalization chart represents the financial valuation of a biotech company developing gene therapy for serious eye diseases. It reflects both the enormous potential of its approach and the serious safety issues identified during trials. Its volatile dynamics tell a dramatic story about the balance between the hope of a breakthrough and the risks to patients.
ADVM - Share of the company's market capitalization Adverum Biotechnologies within the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage gene therapy company focused on treating serious eye diseases. Its sector share reflects both the high potential of its developments and the risks associated with clinical trials. The chart below shows how its weight changes based on news about the safety and efficacy of its therapy.
Market capitalization of the market segment - Pharma eyes
Adverum Biotechnologies is developing gene therapy for eye diseases. The chart below shows the overall market capitalization of the entire ophthalmology sector. Its dynamics reflect the hopes for a one-time treatment capable of restoring vision. Adverum is at the forefront of this complex science.
Market capitalization of all companies included in a broad market index - GURU.Markets
The gene therapy shown in the graph is aimed at treating blindness. Adverum Biotechnologies is developing a single-injection treatment for age-related macular degeneration. Its market cap reflects both the enormous potential of this approach and the serious safety concerns that arose during trials.
Book value capitalization of the company, segment and market as a whole
ADVM - Book value capitalization of the company Adverum Biotechnologies
Adverum's schedule represents capital for gene therapy for eye diseases. The company's book value at the clinical trial stage consists of financial reserves. These assets are used to develop and test a drug that could become a one-time treatment for wet macular degeneration.
ADVM - Share of the company's book capitalization Adverum Biotechnologies within the market segment - Pharma eyes
Adverum Biotechnologies, a gene therapy company, is building its manufacturing base. Its stake in the sector reflects investments in the construction of its own plant to manufacture its eye treatments. This is key to controlling the complex manufacturing process.
Market segment balance sheet capitalization - Pharma eyes
Adverum Biotechnologies is a clinical-stage gene therapy company, making its model intellectually rather than capital-intensive. The company's value lies in its platform and clinical trial data. Compared to the biotech sector, its "light" balance sheet is typical of technology-driven companies.
Book value of all companies included in the broad market index - GURU.Markets
Adverum's assets are not drugs, but a cutting-edge gene therapy platform aimed at treating severe eye diseases that require constant injections. The company's balance sheet reflects the value of its unique "one-shot" technology. The chart shows how much capital has been invested in this development, which has the potential to change the lives of millions.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Adverum Biotechnologies
Adverum Biotechnologies is a company working in gene therapy for eye diseases. Its market capitalization is based on its scientific platform and its hopes of creating a drug capable of restoring vision with a single injection. It's a bet on a scientific breakthrough, not on its current assets.
Market to book capitalization ratio in a market segment - Pharma eyes
Adverum Biotechnologies is a biotech company developing gene therapy for eye diseases. Its market capitalization is a bet on the success of its lead drug. This chart shows the extreme valuation volatility typical of biotech, where clinical news is everything.
Market to book capitalization ratio for the market as a whole
Adverum Biotechnologies is a biotech company developing gene therapy for eye diseases. Its market capitalization is based on the potential of its scientific platform. The chart shows the enormous premium investors are paying for research in one of the most complex and promising areas of modern medicine.
Debts of the company, segment and market as a whole
ADVM - Company debts Adverum Biotechnologies
Adverum Biotechnologies is a company developing gene therapy for eye diseases. Conducting clinical trials in this complex field requires significant and long-term investment. This chart shows how the company raises capital to fund its expensive research and development.
Market segment debts - Pharma eyes
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapy for eye diseases. This is an extremely expensive area of research. This chart shows how the company funds its long-term and risky clinical trials, which are almost always financed through equity capital due to the uncertainty of outcomes.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Adverum Biotechnologies
Adverum Biotechnologies is developing gene therapy for eye diseases. This chart shows how dependent the company is on external funding for its expensive research. High debt in this cutting-edge field of medicine is an extreme risk, as any negative clinical trial results could devastate the company's prospects.
Market segment debt to market segment book capitalization - Pharma eyes
Adverum Biotechnologies is developing gene therapy for serious eye diseases. This is a cutting-edge field of medicine that requires significant investment. This chart compares the company's debt raised for R&D to the total market capitalization of the entire ophthalmic pharmaceutical sector. It illustrates the financial implications of developing drugs that can restore vision.
Debt to book value of all companies in the market
Adverum Biotechnologies is developing gene therapy for eye diseases. This is a cutting-edge but highly capital-intensive field. The chart demonstrates how the company finances its long-term research. Low debt may indicate a focus on equity, a common strategy for biotech companies in clinical trials.
P/E of the company, segment and market as a whole
P/E - Adverum Biotechnologies
This chart for Adverum Biotechnologies, a company developing gene therapy for eye diseases, is a story of hope and failure. Investors' assessment of its potential profitability is heavily dependent on the safety data of its drugs. The trajectory reflects faith in the company's ability to overcome past challenges and prove the effectiveness of its approach.
P/E of the market segment - Pharma eyes
This chart reflects the average valuation for the speculative gene therapy sector—the benchmark for Adverum. Comparison with this metric clearly demonstrates how investors assess the company's risks related to the safety of its drugs. A valuation significantly below the average indicates deep market skepticism.
P/E of the market as a whole
Adverum Biotechnologies is a gene therapy company for serious eye diseases. Its goal is to create a drug that can be administered once and produce long-lasting effects. This is a high-risk development. This chart shows the market's risk appetite. It provides insight into how the market views Adverum's scientific data and the enormous potential of its therapy if clinical trials are successful.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Adverum Biotechnologies
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapy for the treatment of serious eye diseases. This chart reflects analyst expectations for the results of its clinical trials, highlighting the hope that a single injection will provide long-term therapeutic benefit.
%20P%2FE%20Adverum%20Biotechnologies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Adverum-Biotechnologies&v=1772674597534 "Chart of the company's future (projected) P/E Adverum Biotechnologies")
Future (projected) P/E of the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage biopharmaceutical company developing gene therapy for serious eye diseases. This chart compares its future profitability expectations with those of the biotech sector. It demonstrates how the market views the potential of its therapy, which may require just one injection, and the risks associated with its clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772674597578 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapy for eye diseases. This chart reflects overall risk appetite. Adverum prioritizes the safety and efficacy of its drugs. A positive market environment helps with funding, but cannot overcome disappointing results.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772674597611 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Adverum Biotechnologies
Adverum Biotechnologies is a clinical-stage biotechnology company developing gene therapies for the treatment of serious eye diseases. This chart illustrates the long and capital-intensive process of developing innovative drugs. Financial results reflect the company's significant investment in research and clinical trials.
Profit of companies in the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapy for the treatment of serious eye diseases. Its goal is to create single-dose injections with long-lasting effects. This chart shows the financial climate in the ophthalmic pharmaceutical sector, reflecting the potential of breakthrough technologies in the treatment of vision diseases.
Overall market profit
Adverum Biotechnologies is developing gene therapy for eye diseases. The company's success depends solely on the results of clinical trials and regulatory approval. The need for blindness treatment is independent of the stock market or GDP. However, investor sentiment related to the overall economic outlook influences the company's valuation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Adverum Biotechnologies
Adverum Biotechnologies is developing gene therapy for the treatment of serious eye diseases. This is a cutting-edge but risky area of medicine. This chart reflects the speculative expectations of analysts, who are weighing the enormous potential of their technology against the high risks associated with gene therapy clinical trials.
%20profit%20of%20the%20company%20Adverum%20Biotechnologies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Adverum-Biotechnologies&v=1772674597697 "Graph of future (projected) profit of the company Adverum Biotechnologies")
Future (predicted) profit of companies in the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage gene therapy company focused on treating serious eye diseases. This chart shows forecasts for the biotech sector. Adverum's future profitability depends on the success of its core program, which could offer a one-time treatment for patients requiring continuous injections, representing a breakthrough.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772674597714 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Adverum Biotechnologies is developing gene therapy for eye diseases. Like many biotech companies, its key success factors are clinical trial results and access to funding. This chart, illustrating overall profit expectations, highlights the investment climate, which affects funding for long-term research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772674597732 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Adverum Biotechnologies
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapy for serious eye diseases. This chart shows that the company's valuation is entirely future-driven. It reflects investor expectations for the success of its clinical trials and the potential to transform eye disease treatment.
P/S market segment - Pharma eyes
Adverum Biotechnologies is a biopharmaceutical company developing gene therapy for the treatment of serious eye diseases. Its goal is a single injection with long-term benefits. This chart reflects the average biotech valuation, helping to understand how the market values the potential of Adverum's breakthrough technology to change the standard of care in ophthalmology.
P/S of the market as a whole
Adverum Biotechnologies is developing gene therapy for the treatment of serious eye diseases. This is a cutting-edge field of medicine with high potential. This graph of average market revenue estimates clearly demonstrates that the company's valuation is based not on current sales, but on investors' hopes for a long-term and effective treatment for blindness.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Adverum Biotechnologies
Adverum Biotechnologies is a gene therapy company targeting severe eye diseases. This chart is a barometer of hopes and risks. The valuation is based on the enormous potential revenue from a single, life-changing treatment, but it is entirely dependent on successful and safe clinical trials.
%20P%2FS%20Adverum%20Biotechnologies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Adverum-Biotechnologies&v=1772674597803 "The graph of the company's future (projected) P/S Adverum Biotechnologies")
Future (projected) P/S of the market segment - Pharma eyes
Adverum Biotechnologies is a company developing gene therapy for serious eye diseases. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in the potential of its "one shot for life" approach and the success of its clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772674597818 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Adverum Biotechnologies is a gene therapy company in clinical trials, specializing in the treatment of serious eye diseases. This chart shows general expectations for future revenue, and Adverum is an example of a source of these revenues. The success of its "one shot for life" approach could revolutionize ophthalmology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772674597823 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Adverum Biotechnologies
Adverum Biotechnologies is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of serious eye diseases. Because the company does not yet have any approved products, its revenue, as shown in this chart, will likely be nonexistent or will come from collaboration agreements rather than sales.
Sales of companies in the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage gene therapy company focused on treating serious eye diseases. Their goal is to develop drugs that can be administered once. This graph reflects the enormous potential of the ophthalmology market, where gene therapies like Adverum's could offer revolutionary treatment.
Overall market sales
Adverum Biotechnologies is a biotech company developing gene therapy for eye diseases. Its future depends on the results of clinical trials and its ability to raise capital. The growth in total economic revenue, reflected in this chart, creates a favorable investment climate, making it easier for companies like Adverum to finance their long-term R&D projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Adverum Biotechnologies
Adverum Biotechnologies is a biotech company developing gene therapy for the treatment of serious eye diseases. Its goal is to create a single injection that will provide long-term therapeutic effects. This graph reflects analysts' expectations for the clinical trial results of this potentially revolutionary technology.
%20sales%20of%20the%20company%20Adverum%20Biotechnologies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Adverum-Biotechnologies&v=1772674597913 "Schedule of future (projected) sales of the company Adverum Biotechnologies")
Future (projected) sales of companies in the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage company developing gene therapies for the treatment of serious eye diseases. This chart shows the outlook for the ophthalmology pharmaceutical sector, allowing us to appreciate the revolutionary potential of Adverum's approach for patients at risk of vision loss.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772674597933 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Adverum Biotechnologies, which works in gene therapy for eye diseases, sees this chart as an indicator of investment appetite for breakthrough medicine. The strong economics reflected here are driving capital flows into long-term, high-risk projects that could radically change approaches to treating blindness.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772674597946 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Adverum Biotechnologies
Adverum Biotechnologies is a company at the forefront of gene therapy for serious eye diseases. Being in the clinical stage, it incurs significant R&D expenditures. This chart illustrates the cost of innovation, showing how investments are channeled into clinical trials that could one day lead to the development of a revolutionary and profitable drug.
Market segment marginality - Pharma eyes
Adverum Biotechnologies is developing gene therapy for serious eye diseases. In this cutting-edge field of medicine, operational efficiency is directly linked to the cost and speed of clinical trials. This chart provides insight into how efficiently the company utilizes its capital compared to other biotech firms.
Market marginality as a whole
Adverum Biotechnologies is a biotech company developing gene therapy for eye diseases. This chart shows average profitability, and Adverum is working on a potential one-time treatment that could change patients' lives. Their financial history is marked by high R&D expenditures for the sake of a potential breakthrough.
Employees in the company, segment and market as a whole
Number of employees in the company Adverum Biotechnologies
Adverum Biotechnologies is a company developing gene therapy for serious eye diseases. Its team, visible in this graph, consists of highly qualified scientists and clinicians. The size of its staff is an indicator of the intensity of its research and development activities and the complexity of its clinical trials.
Share of the company's employees Adverum Biotechnologies within the market segment - Pharma eyes
Adverum Biotechnologies is developing gene therapy for the treatment of serious eye diseases. In this cutting-edge field, its greatest asset is the top minds in ophthalmology and genetic engineering. The chart shows the percentage of all scientists Adverum has in this niche, a measure of its scientific potential and ambition to create a long-term treatment.
Number of employees in the market segment - Pharma eyes
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapies for eye diseases. Its core asset is its team of scientists and clinicians. This chart shows how the company invests in its research. The staffing dynamics reflect progress in conducting complex and expensive clinical trials.
Number of employees in the market as a whole
Adverum Biotechnologies develops gene therapy for eye diseases. For companies at the forefront of science, the overall economic climate is secondary. This chart shows overall employment, but for Adverum, clinical trial results are crucial, as they can attract millions in investment to expand the team.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Adverum Biotechnologies (ADVM)
Adverum Biotechnologies is a gene therapy company. Its market capitalization is based on the potential of its scientific developments. This chart shows that the market values intellectual property. A sky-high per-employee ratio is the norm for a company at the cutting edge of science.
%20of%20the%20company%20Adverum%20Biotechnologies%20(ADVM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Adverum-Biotechnologies-ADVM&v=1772674598356 "Chart of market capitalization per employee (in thousands of dollars) of the company Adverum Biotechnologies (ADVM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Adverum Biotechnologies is a company developing gene therapy for eye diseases. Its value depends almost entirely on the success of its clinical trials. This metric demonstrates how highly investors value the company's scientific potential per team member. A comparison with the industry will demonstrate the market's confidence in its specific approach.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772674598367 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Adverum Biotechnologies is a clinical-stage biotech company developing gene therapy for eye diseases. Its value lies in the potential of one or two drugs. This chart demonstrates the enormous value the market places on a small team of scientists, as a successful drug could become a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772674598374 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Adverum Biotechnologies (ADVM)
Adverum Biotechnologies is a biotech company specializing in gene therapy for eye diseases. It's a high-stakes R&D business. This negative graph represents the investment phase, reflecting how much capital the company is investing in each of its scientists to advance this complex therapy through clinical trials.
%20Chart%20Adverum%20Biotechnologies%20(ADVM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Adverum-Biotechnologies-ADVM&v=1772674598378 "Company Profit Per Employee (in thousands of dollars) Chart Adverum Biotechnologies (ADVM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Adverum Biotechnologies (ADVM) is a clinical-stage biotech company focused on gene therapy for eye diseases. This is one of the most complex and expensive areas of R&D. This chart shows how effectively the team of scientists and management utilizes significant capital to advance their candidates through clinical trials, creating future value.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772674598400 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Adverum Biotechnologies is a biotech company specializing in gene therapy for eye diseases. This is one of the most complex and expensive areas of R&D. This chart clearly shows that the company is in a deep investment phase. The enormous investment in highly qualified scientists leads to significant losses per employee, which is typical for companies working on breakthrough technologies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772674598404 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Adverum Biotechnologies (ADVM)
Adverum Biotechnologies is a company developing gene therapy for eye diseases. At the clinical trial stage, this graph reflects scientific potential, not current sales. Revenue per employee, if any, typically comes from upfront payments from partners who believe in their technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Adverum-Biotechnologies-ADVM&v=1772674598415 "Sales chart per company employee Adverum Biotechnologies (ADVM)")
Sales per employee in the market segment - Pharma eyes
Adverum Biotechnologies is a gene therapy company specializing in the treatment of serious eye diseases. This is cutting-edge science. This chart shows the average revenue per employee in the sector. For a company in clinical trials, this is a benchmark. It demonstrates the level of productivity required in biotech to successfully monetize breakthrough, but very expensive, treatments.
Sales per employee for the market as a whole
Adverum Biotechnologies (ADVM) is a clinical-stage biotech company specializing in gene therapy for eye diseases. It is a knowledge-intensive R&D company. Revenue during the research phase is minimal (from partnerships). This chart shows the current return on investment per scientist in anticipation of a breakthrough in blindness treatment.
Short shares by company, segment and market as a whole
Shares shorted by company Adverum Biotechnologies (ADVM)
Adverum Biotechnologies is a gene therapy company for eye diseases. The company encountered serious safety issues (inflammation) in its early trials. This chart shows the number of investors betting that the company will fail to overcome these toxicity issues, rendering its lead drug candidate unviable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Adverum-Biotechnologies-ADVM&v=1772674598470 "Short Shares Chart for the Company Adverum Biotechnologies (ADVM)")
Shares shorted by market segment - Pharma eyes
Adverum Biotechnologies is developing gene therapy for eye diseases such as wet AMD. It's a risky field. This chart illustrates the skepticism surrounding the entire niche. Its rise suggests investors are betting heavily against gene therapy for the eye, perhaps fearing serious side effects that could derail the entire industry.
Shares shorted by the overall market
Adverum Biotechnologies is a biotech company developing gene therapy for eye diseases. This is an extremely complex and expensive R&D area. This chart illustrates the overall market pessimism. For Adverum, which has faced safety issues in the past, the growing fear means investors have zero tolerance for any further setbacks.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Adverum Biotechnologies (ADVM)
This graph demonstrates Adverum's high sensitivity to clinical data. The company is developing gene therapy for the treatment of wet macular degeneration (an eye disease). This is a huge market. Positive efficacy data causes euphoria and "overheating" (above 70). However, in ocular gene therapy, safety is crucial. Any reports of side effects (such as inflammation) lead to immediate panic (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Adverum-Biotechnologies-ADVM&v=1772674598534 "RSI 14 indicator chart for the company's stock Adverum Biotechnologies (ADVM)")
RSI 14 Market Segment - Pharma eyes
Adverum (ADVM) is a "biotech" vision "savior." They are developing a *"one-time"* *gene therapy* (AAV) for the treatment of *blindness* (AMD, DME). The "Pharma Eyes" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It is vital to understand: is ADVM's growth due to their R&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Adverum (ADVM) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADVM (Adverum Biotechnologies)
Adverum (ADVM) is a biotech company developing a one-shot gene therapy for the treatment of serious eye diseases (such as wet AMD). This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of this technology, its risks, and its potential in the ophthalmology market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADVM-Adverum-Biotechnologies&v=1772674598568 "A chart showing analyst consensus forecasts for the expected stock price. ADVM (Adverum Biotechnologies)")
The difference between the consensus estimate and the actual stock price ADVM (Adverum Biotechnologies)
Adverum (ADVM) is a biotech developing a one-shot gene therapy for severe eye disease (AMD). It's an R&D bet on a breakthrough. This chart shows the "hope gap." It measures the difference between the price (which reflects risk) and the consensus target, reflecting the enormous potential analysts see in their therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADVM-Adverum-Biotechnologies&v=1772674598572 "A chart showing the difference between the consensus forecast and the actual stock price. ADVM (Adverum Biotechnologies)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Adverum Biotechnologies is a biotech company developing a one-shot gene therapy for the treatment of severe eye diseases (wet AMD). This is high-risk R&D. This chart shows analysts' overall expectations for the ophthalmic pharmaceutical sector. It reflects whether experts believe gene therapy can be successful in ophthalmology.
Analysts' consensus forecast for the overall market share price
Adverum is a clinical-stage biotech company working on gene therapy for eye diseases. It's a risky R&D venture. This chart, which measures the market's overall risk appetite, is crucial. When optimism prevails, investors are willing to fund capital-intensive R&D projects. When pessimism rises, funding for companies like ADVM becomes scarce.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Adverum Biotechnologies
Adverum Biotechnologies is a biotech company focused on one of the most challenging yet lucrative targets: gene therapy for wet age-related macular degeneration (AMD), the leading cause of blindness. This chart is a clear indicator of faith in their R&D. Its dynamics are a roller coaster of progress, reflecting their clinical data, their struggle with safety issues, and their chances of success in this highly complex field.
AKIMA Market Segment Index - Pharma eyes
Adverum Biotechnologies (ADVM) is a clinical-stage gene therapy company developing single-dose injections to treat severe eye diseases such as wet age-related macular degeneration. The chart shows the average index for the segment, helping investors weigh Adverum's high risk and potential breakthrough against the average ophthalmic pharmaceutical sector.
The AKIM Index for the overall market
Adverum Biotechnologies is a gene therapy company developing a single-dose treatment (Ixo-vec) for wet AMD (an eye disease). This market average chart is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this innovative ophthalmology platform.
